11 November 2026

# Nanosonics' CORIS® secures second FDA 510(k) clearance for expanded endoscope indications

Nanosonics Limited (ASX: NAN), a leader in infection prevention solutions, today announces the United States Food and Drug Administration (FDA) has granted a second 510(k) clearance for expanded endoscope indications for its innovative CORIS System, expanding the range of endoscopes that can be reprocessed using the device. The expansion includes a number of high-volume colonoscopes and gastroscopes. Building on the De Novo clearance and the first 510(k) clearance, this second clearance advances Nanosonics' roadmap to expand CORIS across a broader range of endoscope indications.

"Securing our second FDA 510(k) clearance is another important milestone for the CORIS System and demonstrates continued execution against our regulatory and commercialisation strategy, and planned launch activities in the United States. We remain focused on progressively broadening the range of endoscopes that can be reprocessed with CORIS across all our key geographic markets," said Michael Kavanagh, CEO & President of Nanosonics.

The CORIS System is an automated endoscope channel cleaner designed to improve the cleaning of flexible endoscope channels, a critical first step in the reprocessing of reusable endoscopes.

**For more information, please contact:**

Catherine Strong, Head of Investor Relations and Corporate Communications
+61 (0)406 759 268, c.strong@nanosonics.com

Authorised by the Chair of the Nanosonics Limited Board.

CORIS® is a registered trade mark of Nanosonics Limited.